Article Data

  • Views 881
  • Dowloads 192

Systematic review

Open Access Special Issue

Insights into association between urolithiasis and prostate cancer

  • Xiaolu Sun1,†
  • Bhuman Deep Kour2,3,4,†
  • Xiangtao Wang1
  • Xiufang Hu5
  • Yufen Wang6
  • Sugunakar Vuree2,4

1Department of Urology, Shandong Provincial Third Hospital, Shandong University, 250031 Jinan, China

2Department of Biotechnology, School of Bioengineering and Biosciences Lovely Professional University, 144111 Punjab, India

3Department of Biotechnology and Bioinformatics, Birla Institute of Scientific Research (BISR), 302021 Rajasthan, India

4BIOinformatics CLUb for Experimenting Scientists (Bioclues.org), India

5Department of Internal medicine, The People Hospital of Huaiyin, 250021 Jinan, China

6Department of Padiatric, Shandong Provincial Third Hospital, Shandong University, 250031 Jinan, China

DOI: 10.31083/jomh.2021.070 Vol.17,Issue 4,September 2021 pp.52-61

Submitted: 24 January 2021 Accepted: 04 March 2021

Published: 30 September 2021

*Corresponding Author(s): Yufen Wang E-mail: wangyufen521@sina.cn
*Corresponding Author(s): Sugunakar Vuree E-mail: sugunakar.24344@lpu.co.in

† These authors contributed equally.

PDF (1.56 MB) Supplementary material

Abstract

Background and objective: Urolithiasis or renal stones form a major urinary tract infection with formation of calcifications in the bladder and uterus. With the lifestyle diseases burgeoning, the renal stones have become a common cause with an approximate 1 in 1000 people affected all over the world with a risk ratio of 3 : 1 in men and women. On the other hand, prostate or genitourinary cancers are well documented to be associated with urolithiasis.

Methods: A gene list was prepared from the published NCBI dataset, comprising all the genes related to urolithiasis primarily with mutations (both pathogenic and likely pathogenic Single nucleotide polymorphisms, SNP's) for every particular gene screened later from the published datasets. To see the interactions among all the potential genetic factors, PPI based tools were used and an interaction map was prepared. For the characterization of mutations, we have used gnomAD for verifying all the SNPs whether they are synonymous or nonsynonymous mutations.

Results: We outlined the list of genes and discussed the systems bioinformatics integrated approach associated with it.

Conclusion: We found a large number of genes common to them and their association is subtly known for immunomodulatory response.

Keywords

Urolithiasis; Genitourinary cancer; Prostate cancer; Renal/kidney stones; Hyperuricemia; Calcium homeostasis

Cite and Share

Xiaolu Sun,Bhuman Deep Kour,Xiangtao Wang,Xiufang Hu,Yufen Wang,Sugunakar Vuree. Insights into association between urolithiasis and prostate cancer. Journal of Men's Health. 2021. 17(4);52-61.

References

[1] Hemminki K, Hemminki O, Försti A, Sundquist J, Sundquist K, Li X. Familial risks between urolithiasis and cancer. Scientific Reports. 2018; 8: 3083.

[2] Arafa MA, Rabah DM. Study of quality of life and its determinants in patients after urinary stone fragmentation. Health and Quality of Life Outcomes. 2010; 8: 119.

[3] Taguchi K, Yasui T, Milliner DS, Hoppe B, Chi T. Genetic risk factors for idiopathic urolithiasis: a systematic review of the literature and causal network analysis. European Urology Focus. 2017; 3: 72–81.

[4] Eggermann T. Review: genetics of urolithiasis. European Medical Journal. 2014; 29: 1–7.

[5] Roehrborn CG. Acute relief or future prevention: is urology ready for preventive health care? Urology. 2000; 56: 12–19.

[6] Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. International Journal of Urology. 2018; 25: 524–531.

[7] Rawla P. Epidemiology of prostate cancer. World Journal of Oncology. 2019; 10: 63–89.

[8] Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: report from National Cancer Registry Programme, India. JCO Global Oncology. 2020; 6: 1063–1075.

[9] Li JKM, Chiu PKF, Ng C. The impact of microbiome in urological diseases: a systematic review. International Urology and Nephrology. 2019; 51: 1677–1697.

[10] Canales BK, Anderson L, Higgins L, Ensrud-Bowlin K, Roberts KP, Wu B, et al. Proteome of human calcium kidney stones. Urology. 2010; 76: 1017.e13-1017.e20.

[11] Chu KF, Rotker K, Ellsworth P. The impact of obesity on benign and malignant urologic conditions. Postgraduate Medicine. 2013; 125: 53–69.

[12] Tamma SM, Shorter B, Toh K, Moldwin R, Gordon B. Influence of polyunsaturated fatty acids on urologic inflammation. International Urology and Nephrology. 2015; 47: 1753–1761.

[13] Stock A. Analysis of methods for extracting matrix proteins from human kidney stones. Urology & Nephrology Open Access Journal. 2017; 4: 00111.

[14] Fujita K, Ewing CM, Isaacs WB, Pavlovich CP. Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. International Journal of Cancer. 2011; 129: 424–432.

[15] Jurecekova J, Babusikova E, Kmetova Sivonova M, Drobkova H, Petras M, Kliment J, et al. Association between interleukin-18 variants and prostate cancer in Slovak population. Neoplasma. 2017; 64: 148–155.

[16] Lebel-Binay S, Thiounn N, De Pinieux G, Vieillefond A, Debré B, Bonnefoy J, et al. IL-18 is produced by prostate cancer cells and secreted in response to interferons. International Journal of Cancer. 2003; 106: 827–835.

[17] Martínez-Nava GA, Gómez R, Burguete-García AI, Vázquez-Salas RA, Ventura-Bahena A, Torres-Sánchez L. BRCA1 and VDR gene polymorphisms are associated with prostate cancer risk in Mexican men. Molecular Carcinogenesis. 2020; 59: 629–639.

[18] Beyene DA, Daremipouran MR, Apprey V, Naab T, Kassim OO, Copeland RL, et al. The association between the genetic VDR SNP c.907+75C>T and prostate cancer risk is modified by tanning potential. Cancer Genomics & Proteomics. 2020; 17: 739–745.

[19] Cantonero C, Sanchez-Collado J, Gonzalez-Nuñez MA, Salido GM, Lopez JJ, Jardin I, et al. Store-independent Orai1-mediated Ca2+ entry and cancer. Cell Calcium. 2019; 80: 1–7.

[20] Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, et al. Expression of cancer-associated genes in prostate tumors. Experimental Oncology. 2017; 39: 131–137.

[21] Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, et al. Vitamin K epoxide reductase expression and prostate cancer risk. Urologic Oncology. 2016; 35: 112.e13–112.e18.

[22] Gombedza FC, Shin S, Kanaras YL, Bandyopadhyay BC. Abrogation of store-operated Ca2+ entry protects against crystal-induced ER stress in human proximal tubular cells. Cell Death Discovery. 2019; 5: 124.

[23] Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen α–chain. Nature Genetics. 1993; 3: 252–255.

[24] Merchant ML, Cummins TD, Wilkey DW, Salyer SA, Powell DW, Klein JB, et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. American Journal of Physiology-Renal Physiology. 2008; 295: F1254–F1258.

[25] Ganji-Arjenaki M, Nasri H, Rafieian-Kopaei M. Mephrolithiasis as a common urinary system manifestation of inflammatory bowel dis-eases; a clinical review and meta-analysis. Journal of Nephropathology. 2017; 6: 264–269.

[26] Molderings GJ, Solleder G, Kolck UW, Homann J, Schröder D, von Kügelgen I, et al. Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics. Urological Research. 2009; 37: 227–229.

[27] Yilmaz E, Batislam E, Deniz T, Yuvanc E. Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone? Urology. 2009; 73: 32–36.

[28] Wesson JA, Kolbach-Mandel AM, Hoffmann BR, Davis C, Mandel NS. Selective protein enrichment in calcium oxalate stone matrix: a window to pathogenesis? Urolithiasis. 2019; 47: 521–532.

[29] Mishima E, Mori T, Nakajima Y, Toyohara T, Kikuchi K, Oikawa Y, et al. HPRT-related hyperuricemia with a novel p.V35M mutation in HPRT1 presenting familial juvenile gout. CEN Case Reports. 2020; 9: 210–214.

[30] Baştuğ F, Düşünsel R. Pediatric urolithiasis: causative factors, diagnosis and medical management. Nature Reviews Urology. 2012; 9: 138–146.

[31] Kostalova E, Pavelka K, Vlaskova H, Musalkova D, Stiburkova B. Hyperuricemia and gout due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in female carriers: new insight to differential diagnosis. Clinica Chimica Acta. 2015; 440: 214–217.

[32] Ng N, Kaur A, Shenoy M. Recurrent kidney stones in a child with Lesch-Nyhan syndrome: answers. Pediatric Nephrology. 2019; 34: 425–427.

[33] Dussol B, Geider S, Lilova A, Léonetti F, Dupuy P, Daudon M, et al. Analysis of the soluble organic matrix of five morphologically different kidney stones. Evidence for a specific role of albumin in the constitution of the stone protein matrix. Urological Research. 1995; 23: 45–51.

[34] Roula Hamid Mahmoud, Mufeed J. Ewadh KJA-H. Roles of malon-dialdehyde and catalase in serum of Urolithiasis. Medical Journal of Babylon. 2009; 6: 147–153.

[35] Viers BR, Tollefson MK, Patterson DE, Gettman MT, Krambeck AE. Simultaneous vs staged treatment of urolithiasis in patients undergoing radical prostatectomy. World Journal of Clinical Cases. 2014; 2: 698–704.

[36] Chung S, Liu S, Lin H. Association between prostate cancer and urinary calculi: a population-based study. PLoS ONE. 2013; 8: e57743.

[37] Diaz-Convalia E, Arrabal-Polo MA, Cano-Garcia MDC, Dominguez-Amillo A, Canales-Casco N, Arrabal-Martin M. Risk of renal stone formation in patients treated with luteinising hormone-releasing hor-mone analogues for prostate cancer: importance of bone metabolism and urine calcium. International Urology and Nephrology. 2018; 50: 419–425.

[38] McClintock TR, Valovska MI, Kwon NK, Cole AP, Jiang W, Kathrins MN, et al. Testosterone replacement therapy is associated with an increased risk of urolithiasis. World Journal of Urology. 2019; 37: 2737–2746.

[39] Kamisawa K, Kosaka T, Hongo H, Mizuno R, Oya M. Brachytherapy seeds as a nidus for urethral stone formation: a case report. IJU Case Reports. 2019; 2: 206–208.

[40] Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014; 2: 596–605.

[41] Monico CG, Milliner DS. Genetic determinants of urolithiasis. Nature Reviews Nephrology. 2012; 8: 151–162.

[42] Grant MT, Eisner BH, Bechis SK. Ureteral obstruction due to radiolucent atazanavir ureteral stones. Journal of Endourology Case Reports. 2017; 3: 152–154.

[43] Lafaurie M, De Sousa B, Ponscarme D, Lapidus N, Daudon M, Weiss L, et al. Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study. PLoS ONE. 2014; 9: e112836.

[44] Tennakoon S, Aggarwal A, Kállay E. The calcium-sensing receptor and the hallmarks of cancer. Biochimica et Biophysica Acta. 2016; 1863: 1398–1407.

[45] Ahearn TU, Tchrakian N, Wilson KM, Lis R, Nuttall E, Sesso HD, et al. Calcium-sensing receptor tumor expression and lethal prostate cancer progression. The Journal of Clinical Endocrinology and Metabolism. 2016; 101: 2520–2527.

[46] Liao J, Schneider A, Datta NS, McCauley LK. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Research. 2006; 66: 9065–9073.

[47] Bery F, Cancel M, Chantôme A, Guibon R, Bruyère F, Rozet F, et al. The calcium-sensing receptor is a marker and potential driver of neuroendocrine differentiation in prostate cancer. Cancers. 2020; 12: 860.

[48] Schwartz GG, John EM, Rowland G, Ingles SA. Prostate cancer in African-American men and polymorphism in the calcium-sensing receptor. Cancer Biology & Therapy. 2010; 9: 994–999.

[49] Nayak SB, Bhat VR, Upadhyay D, Udupa SL. Copper and cerulo-plasmin status in serum of prostate and colon cancer patients. Indian Journal of Physiology and Pharmacology. 2003; 47: 108–110.

[50] Zubair Mahboob M, Hamid A, Mushtaq N, Batool S, Batool H, Zeeshan N, et al. Data-mining approach for screening of rare genetic elements associated with predisposition of prostate cancer in South-Asian populations. Turkish Journal of Biochemistry. 2019; 44: 848–854.

[51] Mittal RD, Bid HK, Manchanda PK. Genotype and haplotype determination of IL1B (g. −511C>T and g. +3954C>T) and (IL1RN) in pediatric nephrolithiasis. Clinica Chimica Acta. 2006; 379: 42–47.

[52] Culig Z, Steiner H, Bartsch G, Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry. 2005; 95: 497–505.

[53] Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. The American Journal of Pathology. 2001; 159: 2159–2165.

[54] Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. The Prostate. 2000; 42: 239–242.

[55] Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6) BJU International. 2014; 113: 986–992.

[56] Wu C Te, Huang YC, Chen WC, Chen MF. Effect of tumor burden on tumor aggressiveness and immune modulation in prostate cancer: association with IL-6 signaling. Cancers. 2019; 11: 992.

[57] Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA and Cell Biology. 2007; 26: 613–618.

[58] Liu JM, Liu JN, Wei MT, He YZ, Zhou Y, Song XB, et al. Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population. Genetics and Molecular Research. 2013; 12: 820–829.

[59] Cheng I, Krumroy LM, Plummer SJ, Casey G, Witte JS. MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 2007; 16: 1309–1311.

[60] Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. British Journal of Cancer. 2005; 93: 493–497.

[61] Fan YC, Chen WY, Lee K Der, Tsai YC. Tumor-infiltrating leukocytes suppress local inflammation via interleukin-1 receptor antagonist in a syngeneic prostate cancer model. Biology. 2020; 9: 67.

[62] Abolghasemi M, Yousefi T, Maniati M, Qujeq D. The interplay of Klotho with signaling pathway and microRNAs in cancers. Journal of Cellular Biochemistry. 2019; 120: 14306–14317.

[63] Seo M, Kim MS, Jang A, Chung HJ, Noh Y, Kim D, et al. Epigenetic suppression of the anti-aging gene KLOTHO in human prostate cancer cell lines. Animal Cells and Systems. 2017; 21: 223–232.

[64] Xie B, Chen J, Liu B, Zhan J. Klotho acts as a tumor suppressor in cancers. Pathology Oncology Research. 2013; 19: 611–617.

[65] Zhou X, Wang X. Klotho: a novel biomarker for cancer. Journal of Cancer Research and Clinical Oncology. 2015; 141: 961–969.

[66] Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. The Prostate. 2005; 63: 240–251.

[67] Dong J. Prevalent mutations in prostate cancer. Journal of Cellular Biochemistry. 2006; 97: 433–447.

[68] Eroglu M, Yilmaz N, Yalcinkaya S, Ay N, Aydin O, Sezer C. Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients. The Kaohsiung Journal of Medical Sciences. 2013; 29: 368–373.

[69] Abd Al Hamid H, Nasr M, Ibrahim A, Bassiouny K, Abd Al Aziz M. A pilot study of the paraoxonase-1 (Q192 R) gene polymorphism association with prostate cancer in the Egyptian population. Journal of Bioscience and Applied Research. 2020; 6: 1–7.

[70] Quirós I, Sáinz RM, Hevia D, García-Suárez O, Astudillo A, Rivas M, et al. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells. International Journal of Cancer. 2009; 125: 1497–1504.

[71] Zhang L, Xu K, Tang B, Zhang W, Yuan W, Yue C, et al. Association between SOD2 V16a variant and urological cancer risk. Aging. 2020; 12: 825–843.

[72] Miar A, Hevia D, Muñoz-Cimadevilla H, Astudillo A, Velasco J, Sainz RM, et al. Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. Free Radical Biology & Medicine. 2015; 85: 45–55.

[73] Pang X, Xie R, Zhang Z, Liu Q, Wu S, Cui Y. Identification of SPP1 as an extracellular matrix signature for metastatic castration-resistant prostate cancer. Frontiers in Oncology. 2019; 9: 924.

[74] Cantonero C, Sanchez-Collado J, Gonzalez-Nuñez MA, Salido GM, Lopez JJ, Jardin I, et al. Store-independent Orai1-mediated Ca2+ entry and cancer. Cell Calcium. 2019; 80: 1–7.

[75] Safarinejad MR, Shafiei N, Safarinejad S. Association between poly-morphisms in osteopontin gene (SPP1) and first episode calcium oxalate urolithiasis. Urological Research. 2013; 41: 303–313.

[76] Hu B, Wu H, Ma Z, Wu Z, Lu Y, Shi G. Involvement of VKORC1 in the inhibition of calcium oxalate crystal formation in HK-2 cells. Journal of Huazhong University of Science and Technology. 2014; 34: 376–381.

[77] Qin J, Cai Z, Xing J, Duan B, Bai P. Association between calcitonin receptor gene polymorphisms and calcium stone urolithiasis: A meta-analysis. International Brazilian Journal of Urology. 2019; 45: 901–909.

[78] Onaran M, Yilmaz A, Sen I, Ergun MA, Camtosun A, Küpeli B, et al. Heparan sulfate gene polymorphism in calcium oxalate nephrolithiasis. Urological Research. 2009; 37: 47–50.

[79] Kumar G, AlAni RR. Renal stones in two children with two rare etiologies. Saudi Journal of Kidney Diseases and Transplantation. 2018; 29: 1203–1206.

[80] Medina-Escobedo M, González-Herrera L, Villanueva-Jorge S, Martín-Soberanis G. Metabolic abnormalities and polymorphisms of the vitamin D receptor (VDR) and ZNF365 genes in children with urolithiasis. Urolithiasis. 2014; 42: 395–400.

[81] Gee HY, Jun I, Braun DA, Lawson JA, Halbritter J, Shril S, et al. Mutations in SLC26a1 cause nephrolithiasis. American Journal of Human Genetics. 2016; 98: 1228–1234.

[82] Lai K, Lin W, Man K, Tsai C, Chen H, Tsai F, et al. Association of interleukin-18 gene polymorphisms with calcium oxalate kidney stone disease. Scandinavian Journal of Urology and Nephrology. 2010; 44: 20–26.

[83] Dussol B, Geider S, Lilova A, Léonetti F, Dupuy P, Daudon M, et al. Analysis of the soluble organic matrix of five morphologically different kidney stones. Urological Research. 1995; 23: 45–51.

[84] Arcidiacono T, Mingione A, Macrina L, Pivari F, Soldati L, Vezzoli G. Idiopathic calcium nephrolithiasis: a review of pathogenic mecha-nisms in the light of genetic studies. American Journal of Nephrology. 2014; 40: 499–506.

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time

Conferences

    Top